Top

Published in:

01-07-2007 | Review Article

MR Spectroscopy in Neurodegenerative Disease

Author: W. R. Wayne Martin

Published in: Molecular Imaging and Biology | Issue 4/2007

Abstract

Unlike traditional, tracer-based methods of molecular imaging, magnetic resonance spectroscopy (MRS) is based on the behavior of specific nuclei within a magnetic field and the general principle that the resonant frequency depends on the nucleus’ immediate chemical environment. Most clinical MRS research has concentrated on the metabolites visible with proton spectroscopy and measured in specified tissue volumes in the brain. This methodology has been applied in various neurodegenerative disorders, most frequently utilizing measures of N-acetylaspartate as a neuronal marker. At short echo times, additional compounds can be quantified, including myo-inositol, a putative marker for neuroglia, the excitatory neurotransmitter glutamate and its metabolic counterpart glutamine, and the inhibitory neurotransmitter gamma-aminobutyric acid. ³¹P-MRS can be used to study high-energy phosphate metabolites, providing an in vivo assessment of tissue bioenergetic status. This review discusses the application of these techniques to patients with neurodegenerative disorders, including Parkinson’s disease, Alzheimer’s disease, and amyotrophic lateral sclerosis.

Clark JF, Doepke A, Filosa JA, et al. (2006) N-acetylaspartate as a reservoir for glutamate. Med Hypotheses 67:506–512PubMedCrossRef

Urenjak J, Williams SR, Gadian DG, Noble M (1993) Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J Neurosci 13:981–989PubMed

Matthews PM, Francis G, Antel J, Arnold DL (1991) Proton magnetic resonance spectroscopy for metabolic characterisation of plaques in multiple sclerosis. Neurology 41:1251–1256PubMed

Chong WK, Sweeney B, Wilkinson ID, et al. (1993) Proton spectroscopy of the brain in HIV infection: correlation with clinical, immunologic and MR imaging findings. Radiology 188:119–124PubMed

Shino A, Matsuda M, Morikawa S, Inubushi T, Akiguchi I, Handa J (1993) Proton magnetic resonance spectroscopy with dementia. Surg Neurol 39:143–147CrossRef

Gideon P, Henriksen O, Sperling B, et al. (1992) Early time course of N-acetylaspartate, creatine and phosphocreatine, and compounds containing choline in the brain after acute stroke. A proton magnetic resonance spectroscopy study. Stroke 23:1566–1572PubMed

Cwik V, Hanstock C, Allen PS, Martin WRW (1998) Estimation of brainstem neuronal loss in amyotrophic lateral sclerosis with in vivo proton magnetic resonance spectroscopy. Neurology 50:72–77PubMed

Clark JB (1998) N-acetyl aspartate: a marker for neuronal loss or mitochondrial dysfunction. Dev Neurosci 20:271–276PubMedCrossRef

Vion-Dury J, Meyerhoff DJ, Cozzone PJ, Weiner MW (1994) What might be the impact on neurology of the analysis of brain metabolism by in vivo magnetic resonance spectroscopy? J Neurol 241:354–371PubMedCrossRef

10.

Allen PS, Thompson RB, Wilman AH (1997) Metabolite-specific NMR spectroscopy in vivo. NMR Biomed 10:435–444PubMedCrossRef

11.

Christiansen P, Henriksen O, Stubgaard M, Gideon P, Larsson HBW (1993) In vivo quantification of brain metabolites by ¹H MRS using water as an internal standard. Magn Reson Imaging 11:107–108PubMedCrossRef

12.

Michaelis T, Merboldt KD, Bruhn H, Hanicke W, Frahm J (1993) Absolute concentrations of metabolites in the adult human brain in vivo: quantification of localized proton MR spectra. Radiology 187:219–227PubMed

13.

Davie C (1998) The role of spectroscopy in parkinsonism. Mov Disord 13:2–4PubMedCrossRef

14.

Clarke CE, Lowry M (2001) Systematic review of proton magnetic resonance spectroscopy of the striatum in parkinsonian syndromes. Eur J Neurol 8:573–577PubMedCrossRef

15.

Holshauser BA, Komu M, Moller HE, et al. (1995) Localised proton NMR spectroscopy in the striatum of patients with idiopathic Parkinson’s disease: a multicenter pilot study. Magn Reson Med 33:589–594CrossRef

16.

Davie CA, Wenning GK, Barker GJ, et al. (1995) Differentiation of multiple system atrophy from idiopathic Parkinson’s disease using proton magnetic resonance spectroscopy. Ann Neurol 37:204–210PubMedCrossRef

17.

Cruz CJ, Aminoff MJ, Meyerhoff DJ, Graham SH, Weiner MW (1997) Proton MR spectroscopic imaging of the striatum in Parkinson’s disease. Magn Reson Imaging 15:619–624PubMedCrossRef

18.

Tedeschi G, Litvan I, Bonavita S, et al. (1997) Proton magnetic resonance spectroscopic imaging in progressive supranuclear palsy, Parkinson’s disease and corticobasal degeneration. Brain 120:1541–1552PubMedCrossRef

19.

Clarke CE, Lowry M, Horsman A (1997) Unchanged basal ganglia N-acetylaspartate and glutamate in idiopathic Parkinson’s disease measured by proton magnetic resonance spectroscopy. Mov Disord 12:297–301PubMedCrossRef

20.

Ellis CM, Lemmens G, Williams SCR, et al. (1997) Changes in putamen N-acetylaspartate and choline ratios in untreated and levodopa treated Parkinson’s disease: a proton magnetic resonance spectroscopy study. Neurology 49:438–444PubMed

21.

Clarke CE, Lowry M (2000) Basal ganglia metabolite concentrations in idiopathic Parkinson’s disease and multiple system atrophy measured by proton magnetic resonance spectroscopy. Eur J Neurol 7:661–665PubMedCrossRef

22.

O’Neill J, Schuff N, Marks WJ, Feiwell R, Aminoff MJ, Weiner MW (2002) Quantitative ¹H magnetic resonance spectroscopy and MRI of Parkinson’s disease. Mov Disord 17:917–927PubMedCrossRef

23.

Oz G, Terpstra M, Tkac I, et al. (2006) Proton MRS of the unilateral substantia nigra in the human brain at 4 tesla: detection of high GABA concentrations. Magn Reson Med 55:296–301PubMedCrossRef

24.

Lucetti C, del Dotto P, Gambaccini G, et al. (2001) Proton magnetic resonance spectroscopy (¹H-MRS) of motor cortex and basal ganglia in de novo Parkinson’s disease patients. Neurol Sci 22:69–70PubMedCrossRef

25.

Hu MTM, Taylor-Robinson SD, Chaudhuri KR, et al. (1999) Evidence for cortical dysfunction in clinically non-demented patients with Parkinson’s disease: a proton MR spectroscopy study. J Neurol Neurosurg Psychiatry 67:20–26PubMedCrossRef

26.

Camicioli RM, Korzan JR, Foster SL, et al. (2004) Posterior cingulate metabolic changes occur in Parkinson’s disease patients without dementia. Neurosci Lett 354:177–180PubMedCrossRef

27.

Federico F, Simone IL, Lucivero V, et al. (1999) Usefulness of proton magnetic resonance spectroscopy in differentiating parkinsonian syndromes. Ital J Neurol Sci 20:223–229PubMedCrossRef

28.

Watanabe H, Fukatsu H, Katsun M, et al. (2004) Multiple regional ¹H-MR spectroscopy in multiple system atrophy: NAA/Cr reduction in pontine base as a valuable diagnostic marker. J Neurol Neurosurg Psychiatry 75:103–109PubMed

29.

Axelson D, Bakken IJ, Gribbestad IS, Ehrnholm B, Nilsen G, Aasly J (2002) Applications of neural network analyses to in vivo ¹H magnetic resonance spectroscopy of Parkinson disease patients. J Magn Reson Imaging 16:13–20PubMedCrossRef

30.

Tofts PS, Wray S (1988) A critical assessment of methods of measuring metabolite concentrations by NMR spectroscopy. NMR Biomed 1:1–10PubMedCrossRef

31.

Pioro EP, Antel JP, Cashman NR, Arnold DL (1994) Detection of cortical neuron loss in motor neuron disease by proton magnetic resonance spectroscopic imaging in vivo. Neurology 44:1933–1938PubMed

32.

Kalra S, Cashman NR, Caramanos Z, Genge A, Arnold DL (2003) Gabapentin therapy for amyotrophic lateral sclerosis: lack of improvement in neuronal integrity shown by MR spectroscopy. AJNR Am J Neuroradiol 24:476–480PubMed

33.

Kalra S, Genge A, Arnold D (2003) A prospective, randomized, placebo controlled evaluation of corticoneuronal response to intrathecal BDNF therapy in ALS using magnetic resonance spectroscopy: feasibility and results. Amyotroph Lateral Scler Other Motor Neuron Disord 4:22–26PubMedCrossRef

34.

Abe K, Takanashi M, Watanabe Y (2001) Decrease in N-acetylaspartate/creatine ratio in the motor area and the frontal lobe in amyotrophic lateral sclerosis. Neuroradiology 43:537–541PubMedCrossRef

35.

Kaufmann P, Pullman SL, Shungu DC, et al. (2004) Objective tests for upper motor neuron involvement in amyotrophic lateral sclerosis (ALS). Neurology 62:1753–1757PubMed

36.

Cwik VA, Hanstock CC, Allen PS, Martin WRW (1998) Estimation of brainstem neuronal loss in amyotrophic lateral sclerosis with in vivo proton magnetic resonance spectroscopy. Neurology 50:72–77PubMed

37.

Suhy J, Miller RG, Rule R, et al. (2002) Early detection and longitudinal changes in amyotrophic lateral sclerosis by ¹H-MRSI. Neurology 58:773–779PubMed

38.

Kalra S, Hanstock CC, Martin WRW, et al. (2006) Detection of cerebral degeneration in amyotrophic lateral sclerosis using high-field magnetic resonance spectroscopy. Arch Neurol 63:1144–1148PubMedCrossRef

39.

Kalra S, Cashman NR, Genge A, Arnold DL (1998) Recovery of N-acetylaspartate in corticomotor neurons of patients with ALS after riluzole therapy. Neuroreport 9:1757–1761PubMedCrossRef

40.

Schuff N, Capizzano AA, Du AT, et al. (2002) Selective reduction of N-acetyl aspartate in medial temporal and parietal lobes in AD. Neurology 58:928–935PubMed

41.

Jessen F, Block W, Traber F, et al. (2000) Proton MR spectroscopy detects a relative decrease of N-acetylaspartate in the medial temporal lobe of patients with AD. Neurology 55:684–688PubMed

42.

Frederick BD, Lyoo IK, Satlin A, et al. (2004) In vivo proton magnetic resonance spectroscopy of the temporal lobe in Alzheimer’s disease. Prog Neuropsychopharm Biol Psychiatry 28:1313–1322CrossRef

43.

Kantarci K, Petersen RC, Boeve BF, et al. (2004) ¹H MR spectroscopy in common dementias. Neurology 63:1393–1398PubMed

44.

Huang W, Alexander GE, Chang L, et al. (2001) Brain metabolite concentration and dementia severity in Alzheimer’s disease: a ¹H MRS study. Neurology 57:626–632PubMed

45.

Glanville NT, Byers DM, Cook HW, Spence MW, Palmer FB (1989) Differences in the metabolism of inositol and phosphoinositides by cultured cells of neuronal and glial origin. Biochim Biophys Acta 1004:169–179PubMed

46.

Ross AJ, Sachdev PS, Wen W, Brodaty H (2006) Longitudinal changes during aging using proton magnetic resonance spectroscopy. J Gerontol A Biol Sci Med Sci 61A:291–298

47.

Klunk WE, Xu C, Panchalingham K, McClure RJ, Pettegrew JW (1996) Quantitative ¹H and ³¹P MRS of PCA extracts of postmortem Alzheimer’s disease brain. Neurobiol Aging 17:349–357PubMedCrossRef

48.

Catani M, Cherubini R, Howard R, et al. (2001) ¹H-MR spectroscopy differentiates mild cognitive impairment from normal brain aging. Neuroreport 12:2315–2317PubMedCrossRef

49.

Kantarci K, Jack CR Jr, Xu YC, et al. (2000) Regional metabolic patterns in mild cognitive impairment and Alzheimer’s disease. Neurology 55:210–217PubMed

50.

Chantal S, Braun CMJ, Bouchard RW, Labelle M, Boulanger Y (2004) Similar ¹H magnetic resonance spectroscopic metabolic pattern in the medial temporal lobes of patients with mild cognitive impairment and Alzheimer disease. Brain Res 1003:26–35PubMedCrossRef

51.

Valenzuela MJ, Sachdev P (2001) Magnetic resonance spectroscopy in Alzheimer’s disease. Neurology 56:592–598PubMed

52.

Ackl N, Ising M, Schreiber YA, Atiya M, Sonntag A, Auer DP (2005) Hippocampal metabolic abnormalities in mild cognitive impairment and Alzheimer’s disease. Neurosci Lett 384:23–28PubMedCrossRef

53.

Modrego PJ, Fayed N, Pina MA (2005) Conversion from mild cognitive impairment to probably Alzheimer’s disease predicted by brain magnetic resonance spectroscopy. Am J Psychiatry 162:667–675PubMedCrossRef

54.

Falini A, Bozzali M, Magnani G, et al. (2005) A whole brain MR spectroscopy study from patients with Alzheimer’s disease and mild cognitive impairment. Neuroimage 26:1159–1163PubMedCrossRef

55.

Marjanska M, Curran GL, Wengenack TM, et al. (2005) Monitoring disease progression in transgenic mouse models of Alzheimer’s disease with proton magnetic resonance spectroscopy. Proc Natl Acad Sci U S A 102:11906–11910PubMedCrossRef

56.

Dedeoglu A, Choi J-K, Cormier K, Kowall NW, Jenkins BG (2004) Magnetic resonance spectroscopic analysis of Alzheimer’s disease mouse brain that express mutant human APP shows altered neurochemical profile. Brain Res 1012:60–65PubMedCrossRef

57.

von Kienlin M, Kunnecke B, Metzger F, et al. (2004) Altered metabolic profile in the frontal cortex of PS2APP transgenic mice, monitored throughout their life span. Neurobiol Dis 18:32–39CrossRef

58.

DiMauro S (1993) Mitochondrial involvement in Parkinson’s disease: the controversy continues. Neurology 43:2170–2171PubMed

59.

Gu M, Cooper JM, Taanman JW, Schapira AHV (1998) Mitochondrial DNA transmission of the mitochondrial defect in Parkinson’s disease. Ann Neurol 44:177–186PubMedCrossRef

60.

Matthews PM, Allaire C, Shoubridge EA, Karpati G, Carpenter S, Arnold DL (1991) In vivo muscle magnetic resonance spectroscopy in the clinical investigation of mitochondrial disease. Neurology 41:114–120PubMed

61.

Penn AMW, Roberts T, Hodder J, Allen PS, Zhu G, Martin WRW (1995) Generalized mitochondrial dysfunction in Parkinson’s disease detected by magnetic resonance spectroscopy of muscle. Neurology 45:2097–2099PubMed

62.

Rango M, Bonifati C, Bresolin N (2006) Parkinson’s disease and brain mitochondrial dysfunction: a functional phosphorus magnetic resonance spectroscopy study. J Cereb Blood Flow Metab 26:283–290PubMedCrossRef

63.

Fox PT, Raichle ME, Mintun MA, Dence C (1988) Nonoxidative glucose consumption during focal physiologic neural activity. Science 241:462–464PubMedCrossRef

64.

Barbiroli B, Martinelli P, Patuelli A, et al. (1999) Phosphorus magnetic resonance spectroscopy in multiple system atrophy and Parkinson’s disease. Mov Disord 14:430–435PubMedCrossRef

65.

Hu MTM, Taylor-Robinson SD, Chaudhuri KR, et al. (2000) Cortical dysfunction in non-demented Parkinson’s disease patients. A combined ³¹P-MRS and ¹⁸FDG-PET study. Brain 123:340–352PubMedCrossRef

66.

Hoang TQ, Bluml S, Dubowitz DJ, et al. (1998) Quantitative proton-decoupled ³¹P MRS and ¹H MRS in the evaluation of Huntington’s and Parkinson’s diseases. Neurology 50:1033–1040PubMed

67.

Forlenza OV, Wacker P, Nunes PV, et al. (2005) Reduced phospholipid breakdown in Alzheimer’s brains: a ³¹P spectroscopy study. Psychopharmacology (Berl) 180:359–365CrossRef

68.

Jenkins BG, Koroshetz WJ, Beal MF, Rosen BR (1993) Evidence for impairment of energy metabolism in vivo in Huntington’s disease using localized ¹H NMR spectroscopy. Neurology 43:2689–2695PubMed

69.

Morris P, Bachelard H (2003) Reflections on the application of ¹³C-MRS to research on brain metabolism. NMR Biomed 16:303–312PubMedCrossRef

70.

de Graaf RA, Mason GF, Patel AB, Behar KL, Rothman DL (2003) In vivo ¹H-[¹³C]-NMR spectroscopy of cerebral metabolism. NMR Biomed 16:339–357PubMedCrossRef

71.

Gruetter R, Adriany G, Choi I-Y, Henry P-G, Lei H, Oz G (2003) Localized in vivo ¹³C NMR spectroscopy of the brain. NMR Biomed 16:313–338PubMedCrossRef

72.

Hyder F, Patel AB, Gjedde A, Rothman DL, Behar KL, Shulman RG (2006) Neuronal-glial glucose oxidation and glutamatergic-GABAergic function. J Cereb Blood Flow Metab 26:865–877PubMedCrossRef

73.

Lin AP, Shic F, Enriquez C, Ross BD (2003) Reduced glutamate neurotransmission in patients with Alzheimer’s disease—an in vivo ¹³C magnetic resonance spectroscopy study. MAGMA 16:29–42PubMedCrossRef

74.

Provencher SW (2001) Automatic quantitation of localized in vivo ¹H spectra with LCModel. NMR Biomed 14:260–264PubMedCrossRef

Title: MR Spectroscopy in Neurodegenerative Disease
Author: W. R. Wayne Martin
Publication date: 01-07-2007
Publisher: Springer-Verlag
Published in: Molecular Imaging and Biology / Issue 4/2007
Print ISSN: 1536-1632
Electronic ISSN: 1860-2002
DOI: https://doi.org/10.1007/s11307-007-0087-2

At a glance: The STEP trials

Springer Medicine

MR Spectroscopy in Neurodegenerative Disease

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2007

Imaging of Cholinergic and Monoaminergic Neurochemical Changes in Neurodegenerative Disorders

Imaging Non-Dopaminergic Function in Parkinson’s Disease

The Application of Positron-Emitting Molecular Imaging Tracers in Alzheimer’s Disease

Understanding the Placebo Effect: Contributions from Neuroimaging

In Vitro Imaging Techniques in Neurodegenerative Diseases

Animal Models of Neurodegenerative Disease: Insights from In vivo Imaging Studies